Responses
Clinical and epidemiological research
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
Compose a Response to This Article
Other responses
No responses have been published for this article.